AnaptysBio To Present Phase 1 Data On ANB032, Its BTLA Agonist Antibody, At The 32nd EADV Congress
Portfolio Pulse from Benzinga Newsdesk
AnaptysBio is set to present Phase 1 data on ANB032, its BTLA agonist antibody, at the 32nd EADV Congress. This could potentially impact the company's stock performance.
October 11, 2023 | 1:16 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
AnaptysBio's presentation of Phase 1 data on ANB032 at the EADV Congress could influence its stock performance.
The presentation of Phase 1 data on ANB032 by AnaptysBio at the EADV Congress could potentially influence investor sentiment and thus the company's stock performance. However, the exact impact will depend on the data presented and the market's reaction to it.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 100